Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2

Sandoz AG

12/11/2025 14:52

LONDON, Nov 12 (Reuters) - Generic drug giant Sandoz SDZ.S expects unbranded versions of Novo Nordisk's NOVOb.CO popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wednesday.

     "It's unlikely people will launch in January next year, to be brutally honest. I think it'll probably be quarter one, quarter two," said Richard Saynor in an interview.

Sandoz hopes to be one of the first entrants in the Canadian market where Novo's patent for semaglutide for diabetes will expire in January.

 (Reporting by Bhanvi Satija;Editing by Elaine Hardcastle)

 ((Bhanvi.Satija@thomsonreuters.com;))